
|Videos|September 24, 2016
Questions That Remain Regarding Combination, Sequencing With PARP Inhibitors
Author(s)Patricia LoRusso, DO, PhD
Patricia LoRusso, DO, PhD, professor of medicine and associate director of Innovative Medicine at Yale Cancer Center, discusses the key questions that still remain regarding combination and sequencing with PARP inhibitors.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts NDA for Daraxonrasib in Metastatic Pancreatic Cancer
2
Advanced Renal Cell Carcinoma: Tailoring Second-Line Therapy After Prior Immunotherapy
3
FDA Approves Zidesamtinib for Previously Treated ROS1-Positive NSCLC
4
Teclistamab/Talquetamab Reduces Risk of Progression by 89% in R/R Multiple Myeloma
5






























